


Enzaplatovir

Cat. No.:	HY-109004		
CAS No.:	1323077-89-9		
Molecular Formula:	C ₂₀ H ₁₉ N ₅ O ₃		
Molecular Weight:	377.4		
Target:	RSV		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 200 mg/mL (529.94 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.6497 mL	13.2485 mL	26.4971 mL
		5 mM	0.5299 mL	2.6497 mL	5.2994 mL
10 mM		0.2650 mL	1.3249 mL	2.6497 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 6 mg/mL (15.90 mM); Clear solution Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (13.25 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (13.25 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection ^[1] .
IC₅₀ & Target	RSV ^[1]
In Vitro	Respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden. Enzaplatovir is a small-molecule RSV entry inhibitor ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Eric A F Simões, et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018 Mar;7(1):87-120.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA